Status:
COMPLETED
A Study In Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medic...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- A clinical diagnosis type 2 diabetes mellitus.
- Women must not be pregnant or breastfeeding during the study and 30 days after the study.
- Must sign an informed consent form at the study clinic.
- Exclusion criteria:
- Severe chronic diseases that would prevent from participating and completing the study by investigator's judgement.
- Use of an investigational drug within 30 days or 5 half lives before first dose of study medication.
- Insulin use for \> 1 week in past 3 months.
Exclusion
Key Trial Info
Start Date :
August 18 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2006
Estimated Enrollment :
369 Patients enrolled
Trial Details
Trial ID
NCT00256867
Start Date
August 18 2005
End Date
October 31 2006
Last Update
July 2 2018
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Tucson, Arizona, United States, 85745
2
GSK Investigational Site
Fresno, California, United States, 93720
3
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80033
4
GSK Investigational Site
Waterbury, Connecticut, United States, 06708